

## **Diasome Pharmaceuticals, Inc. Announces Issuance of Oral Insulin Patent by the US PTO**

*Oral Hepatic Targeted Insulin technology enables low dose oral insulin therapies for treating Type 1 and Type 2 diabetes*

Cleveland, OH ([PRWEB](#)) February 25, 2015 -- Diasome Pharmaceuticals, Inc. ([www.diasome.com](http://www.diasome.com)) has received notice from its licensor, SDG, Inc., that SDG has received a notice of allowance for its novel oral hepatic targeted insulin technology, called Oral HDV Insulin. This patent, entitled “Orally Bioavailable Lipid Constructs,” has been assigned US Patent Number 8,962,015 and covers composition of matter claims related to the use of Diasome’s proprietary oral Hepatocyte Directed Vesicles (“HDV”) as a system for enabling oral insulin administration.

“While most oral protein and peptide delivery technologies under development require relatively large quantities of the drug in order to be effective, Diasome’s Phase 2 human results demonstrate the efficacy of very low doses of insulin when delivered by the HDV system. The issuance of this new patent further validates and supports Diasome’s strong pipeline of cell specific targeting technologies for treating both forms of diabetes and obesity,” said W. Blair Geho, MD, PhD, Diasome’s Chief Scientific Officer. “This technology has been enabled for late stage human clinical testing by the US FDA, and we look forward to moving forward in our development effort for orally administered protein therapies.”

About Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity.



**Contact Information**

**Robert Geho**

Diasome Pharmaceuticals, Inc.

<http://www.diasome.com>

+1 216-444-7110

**Online Web 2.0 Version**

You can read the online version of this press release [here](#).